跳至主要内容
临床试验/NCT05283889
NCT05283889进行中(未招募)不适用

The Safety and Efficacy of Genicular Radiofrequency Ablation for Patients With Persistent Knee Pain Following Total Knee Arthroplasty - A Triple Blinded Randomized Sham-Controlled Trial

University of Calgary1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2022年5月11日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
44
试验地点
1
主要终点
Average Pain Intensity Over the Prior week (0 - 10)

研究概览

简要总结

Currently, nearly 1 million total knee arthroplasties (TKA) are performed yearly in the United States. Three million are projected to be performed in 2040. Between 15-30% of all patients who undergo TKA have continued pain, reduced quality of life and functional impairments that cannot be attributed to hardware failure/loosening or infection. Treatment options for persistent post TKA pain (failed TKA) are limited. There is a need for minimally invasive, and effective pain and disability modulating interventions for patients with failed TKA. Genicular radiofrequency ablation (GRFA) has been described, refined, and validated as an effective minimally invasive intervention to control refractory knee pain secondary to knee osteoarthritis (OA) as evidenced by three favorable meta-analyses published in 2021 alone.3-5 GRFA is a minimally invasive percutaneous procedure that utilizes thermal energy to coagulate nerves from the knee. Though sometimes used in practice, there is limited research describing and evaluating GRFA for patients with failed TKA. This will be the first trial to evaluate the safety and efficacy of GRFA in patients with failed TKA using a robust study design and up-to-date, evidence-based selection criteria and technique.

详细描述

The general objective of this study is to determine the safety and efficacy of GRFA in patients with failed TKA. The central hypothesis is that GRFA is safe and more efficacious in improving pain and function than sham GRFA. A triple blinded randomized sham-controlled trial design will be used. Patients with failed TKA will be recruited and randomized into either a thermal or sham GRFA group. Patient selection criteria and GRFA procedural technique will incorporate refinements based on expanded understanding from recent research. Outcomes will be assessed prior to and at 3, 6 and 12 months post-GRFA. The primary outcome measures will be between group difference in the change in pain (NRS) between pre- and 6 months post. Secondary outcomes will include safety and changes in function (WOMAC; sit-stand test; strength; range of motion & balance), participants' impression of change, perceived need for revision arthroplasty, analgesic use, and quality-of-life. Crossover will be offered to participants in the sham group at 6 months post-treatment. Data will be analyzed using descriptive, linear mixed-effects model and Kaplan-Meier Survival Curve statistics. The proposed research is innovative and important as it uses a robust study design to evaluate the safety and efficacy of an emerging RFA intervention in a prevalent suffering patient population.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

盲法说明

Triple blinding will be accomplished as follows: operator (RF generator operated by assistant out of sight of operator); participant (local anesthetic administration and cannula placement identical; RF generator makes the same beeping sound for the same duration); assessor (only the study coordinator is aware of group assignment).

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • >1 year post TKA
  • persistent knee pain > 4/10 in intensity on average over the prior week of one of the post-TKA knees
  • refractory to conventional treatment (i.e., physiotherapy, medication, etc.)
  • ≥80% pain relief with a single fluoroscopically guided local anesthetic block using 0.5 mL of 2% lidocaine for the medial and lateral branches of the nerve to the vastus intermedialis, nerve to the vastus lateralis*, inferior medial genicular nerve, infrapatellar branch of the saphenous nerve, and the recurrent fibular nerve. 0.5 mL will be injected over 2 spots (1.5 cm apart) for each of the superior medial and lateral genicular nerves corresponding to the sites of the RF cannulae for the bipolar strip lesions. *Blocks will be combined fluoroscopy/ultrasound guided.

排除标准

  • Infection (peri-prosthetic, joint, systemic, skin/soft tissue overlying the knee to be treated)
  • Prosthetic loosening or failure, periprosthetic fracture
  • Severe psychiatric disorder
  • Non-genicular lower extremity pain source from the spine (i.e., radiculopathy or neurogenic claudication) or peripheral joints (i.e., hip osteoarthritis)
  • Peripheral vascular disease causing vascular claudication
  • Connective tissue/inflammatory joint disease/widespread soft tissue pain disorder
  • Poor tolerance of injection procedures (as observed from the prognostic local anesthetic blocks)
  • Allergy to local anesthetic, synovial expansion into the anticipated path(s) of the local anesthetic needle/RF cannula as determined by ultrasound scanning
  • Uncontrolled bleeding diathesis
  • Pregnancy
  • Pacemaker or neurostimulator
  • Inability to complete Patient-Reported Outcome Measures due to cognitive or language limitations.

研究组 & 干预措施

Group 1 (GRFA)

Experimental

After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.

干预措施: Genicular Radiofrequency Ablation (Procedure)

Group 2 (Sham)

Active Comparator

The same procedure will be employed as per Group 1 - However, the sham procedure will involve no electrical signal applied to the participant.

干预措施: Sham Genicular Radiofrequency Ablation (Procedure)

结局指标

主要结局

Average Pain Intensity Over the Prior week (0 - 10)

时间窗: 6 months

Numerical pain rating scale (0 - 10) with higher scores indicating a worse outcome

Change in pain intensity between pre- and 6-months post-intervention

时间窗: 6 months

Numerical Pain rating scale (NPRS) 6 month minus NPRS pre-intervention, with increased negative scores indicating a better outcome

次要结局

  • Average Pain Intensity Over the Prior Week (0 - 10)(3 and 12-months post-intervention)
  • Analgesic Use(Baseline (Prior to), 3, 6 and 12-months post-intervention)
  • Health-related Quality of Life(Baseline (Prior to), 3, 6 and 12-months post-intervention)
  • The Clinical Global Impressions Scale (CGI)(3, 6 and 12-months post-intervention)
  • Western Ontario and McMaster Universities Arthritis Index (WOMAC)(3, 6 and 12-months post-intervention)
  • Perceived Need for Revision Arthroplasty(Baseline (Prior to), 3, 6 and 12-months post-intervention)
  • Safety - Adverse Events(1-week, 3, 6 and 12-months post-intervention)
  • Proportion of participants exceeding 50% pain relief(6 months)
  • Proportion of participants exceeding Minimal Clinically Important Difference (MCID) pain relief(6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验